Publications by authors named "Jens M Debacker"

Claim this Profile
I
Immune modulation following α and β radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model.
Hannelore Ceuppens, Kirsten De Ridder, Thomas Ertveldt, Katty Zeven, Wout De Mey, Jens M Debacker

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP).
Anne-Sofie De Crem, Philippe Tummers, Herman Depypere, Geert Braems, Rawand Salihi, Jens M Debacker

NPJ Breast Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Method for co-registration of high-resolution specimen PET-CT with histopathology to improve insight into radiotracer distributions.
Luna Maris, Menekse Göker, Jens M Debacker, Kathia De Man, Bliede Van den Broeck

EJNMMI Phys· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential application of [F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma.
Bliede Van den Broeck, Jens M Debacker, Wouter Bauters, David Creytens, Liesbeth Ferdinande

EJNMMI Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.
Katty Zeven, Yoline Lauwers, Lynn De Mey, Jens M Debacker, Tessa De Pauw

Immunother Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choice of surgery in intestinal-type adenocarcinoma of the sinonasal tract: a long-term comparative study.
Tijl Vermassen, Stijn De Keukeleire, Michael Saerens, Sylvester Heerwegh, Jens M Debacker

Eur Arch Otorhinolaryngol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status and future expectations of nanobodies in oncology trials.
Tessa De Pauw, Lynn De Mey, Jens M Debacker, Geert Raes, Jo A Van Ginderachter

Expert Opin Investig Drugs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety assessment of fluorescently labeled anti-EGFR Nanobodies in healthy dogs.
Nayra Cristina Herreira do Valle, Simone Janssen, Marcus C M Stroet, Sofie Pollenus, Sonja Van den Block, Jens M Debacker

Front Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct co-registration of [F]FDG uptake and histopathology in surgically excised malignancies of the head and neck: a feasibility study.
Jens M Debacker, Luna Maris, Fleur Cordier, David Creytens, Philippe Deron

Eur J Nucl Med Mol Imaging· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Resolution F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept.
Jens M Debacker, Vanessa Schelfhout, Lieve Brochez, David Creytens, Yves D'Asseler

J Clin Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis.
Jens M Debacker, Odrade Gondry, Tony Lahoutte, Marleen Keyaerts, Wouter Huvenne

Cancers (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying non-otologic risk factors for tinnitus: A systematic review.
Ann N Deklerck, Jens M Debacker, Hannah Keppler, Ingeborg J M Dhooge

Clin Otolaryngol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis